top of page

Publications

Updated articles on PubMed

 

Updated citations on google scholar

​​

  1. Yehuda S. & Padler-Karavani V. (2024). Cracking the diversity of sweet drugs. Nature Chemical biology News and Views,  20:1397–1398. 

  2. Singh Kooner A., Yu H., Leviatan Ben-Arye S., Padler-Karavani V., Chen X. (2024). Broad-Spectrum Legionaminic Acid-Specific Antibodies in Pooled Human IgGs Revealed by Glycan Microarrays with Chemoenzymatically Synthesized Nonulosonosides. Molecules. 29(16):3980. 

  3. Guimbretière G., Sénage T., e Boureau AS., Roos JC., Bernard Q., Carlier B., Veziers J., Cueff C., Piriou N., Coste G., Fellah I., Lelarge C., Capoulade R., Jaafar P., Manigold T., Letocart V., Warin-Fresse K., Guérin P., Costa C., Vadori M, Galinañes M., Manez R., Soulillou JP., Cozzi E., Padler-Karavani V., Serfaty JM., Roussel JC, Le Tourneau T. (2024). Calcification of surgical aortic bioprostheses and its impact on clinical outcome. Eur Heart J Cardiovasc Imaging 25(9):1226-1234.

  4. Marglous S., Brown CE., Padler-Karavani V., Cummings RD. and Gildersleeve JC. (2024). Serum Antibody Screening Using Glycan arrays. Chem. Soc. Review. 53, 2603 - 2642

  5. Casós K., Llatjós R., Blasco-Lucas A., Kuguel SG., Sbraga F., Galli C., Padler-Karavani V., Le Tourneau T., Vadori M., Perota A., Roussel JC., Bottio T., Cozzi E., Soulillou JP., Galiñanes M., Máñez R., Costa C. (2023). Differential Immune Response to Bioprosthetic Heart Valve Tissues in the α1,3Galactosyltransferase-Knockout Mouse Model. Bioengineering 13;10(7):833. 

  6. Galiñanes M., Casós K., Blasco-Lucas A., Permanyer E., Máñez R., Le Tourneau T., Barquinero J., Schwartz Jr S., Roussel JC., Fellah-Hebia I., Sénage T., Evangelista A., Badano LP., Ruiz-Majoral A., Galli C., Padler-Karavani V., Soulillou JP., Vidal X., Cozzi E., Costa C. (2022). Oxidative Stress in Structural Valve Deterioration: A Longitudinal Clinical Study. Biomolecules.12(11):1606.

  7. Parhi L., Abed J., Shhadeh A., Alon-Maimon T., Udi S., Ben-Arye SL., Tam J., Parnas O., Padler-Karavani V., Goldman-Wohl D., Yagel S., Mandelboim O., Bachrach G. (2022). Placental colonization by Fusobacterium nucleatum is mediated by binding of the Fap2 lectin to placentally displayed Gal-GalNAc. Cell Rep. 22;38(12).

  8. Senage T., Paul A., TourneauTL., Fellah-Hebia F, Vadori M., Bashir S., Galiñanes M., Bottio T., Gerosa G., Evangelista A.,  Badano LP., Nassi A., Costa C., Cesare G, Manji RA, Cueff de Monchy C., Piriou N., Capoulade R., Serfaty JM., Guimbretière G., Dantan E., Ruiz-Majoral A., Coste du Fou G., Leviatan Ben-Arye S., Govani L., Yehuda S., Bachar Abramovitch S., Amon R, Reuven EM., Atiya-Nasagi Y., Yu H., Lop L., Casós K., Kuguel SG., Blasco-Lucas A., Permanyer E., Sbraga F., Llatjós R., Moreno-Gonzalez G., Sánchez-Martínez M., Breimer ME., Holgersson J., Teneberg S., Pascual-Gilabert M., Nonell-Canals A., Takeuchi Y., Chen X., Mañez R., Roussel JC., Soulillou JP., Cozzi E.& Padler-Karavani V. (2022). The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration. Nature Medicine. 283-294.

  9. Shanthamurthy CD, Gimeno A, Leviatan Ben-Arye S, Kumar NV, Jain P, Padler-Karavani V, Jiménez-Barbero J, Kikkeri R. (2021). Sulfation Code and Conformational Plasticity of l-Iduronic Acid Homo-Oligosaccharides Mimic the Biological Functions of Heparan Sulfate. ACS Chem Biol. 2481-2489. 

  10. Borenstein-Katz A, Warszawski S, Amon R, Eilon M, Cohen-Dvashi H, Leviatan Ben-Arye S, Tasnima N, Yu H, Chen X, Padler-Karavani V, Fleishman SJ, Diskin R.J. (2021). Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies. Mol Biol. Jun 11;433(15):167099.

  11. Noy-Porat T, Mechaly A, Levy Y, Makdasi E, Alcalay R, Gur D, Aftalion M, Falach R, Leviatan Ben-Arye S, Lazar S, Zauberman A, Epstein E, Chitlaru T, Weiss S, Achdout H, Edgeworth JD, Kikkeri R, Yu H, Chen X, Yitzhaki S, Shapira SC, Padler-Karavani V, Mazor O, Rosenfeld R. (2021). Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice. iScience.24(5):102479. 

  12. Jain P, Shanthamurthy CD, Leviatan Ben-Arye S, Yehuda S, Nandikol SS, Thulasiram HV, Padler-Karavani V, Kikkeri R. (2021). Synthetic heparan sulfate ligands for vascular endothelial growth factor to modulate angiogenesis. Chem Commun 57(28):3516-3519.

  13. Shanthamurthy CD, Leviatan Ben-Arye S, Kumar NV, Yehuda S, Amon R, Woods RJ, Padler-Karavani V, Kikkeri R. (2021). Heparan Sulfate Mimetics Differentially Affect Homologous Chemokines and Attenuate Cancer Development. J Med Chem. 25;64(6):3367-3380.

  14. Amon R, Rosenfeld R, Perlmutter S, Grant O.C,  Yehuda S, Borenstein-Katz A,  Alcalay R, Marshanski R, Yu H, Diskin R, Woods R.J, Chen X, Padler-Karavani V. (2020). Directed Evolution of Therapeutic Antibodies Targeting Glycosylation in Cancer. Cancers 12(10), 2824.

  15. Bashir S, Fezeu LK, Leviatan Ben-Arye S, Yehuda S, Reuven EM, Szabo de Edelenyi F, Fellah-Hebia I, Le Tourneau T, Imbert-Marcille BM, Drouet EB, Touvier M, Roussel JC, Yu H, Chen X, Hercberg S, Cozzi E, Soulillou JP, Galan P, Padler-Karavani V. (2020). Association between Neu5Gc carbohydrate and serum antibodies against it provides the molecular link to cancer: French NutriNet-Santé study. BMC Med.18(1):262.

  16. Soulillou JP, Padler-Karavani V. (2020) Editorial: Human Antibodies Against the Dietary Non-human Neu5Gc-Carrying Glycans in Normal and Pathologic States. Front Immunol. eCollection.

  17. Yehuda S, Padler-Karavani V. (2020). Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid. Front Immunol. 11:21.

  18. Cohen-Dvashi H, Amon R, Agans KN, Cross RW, Borenstein-Katz A, Mateo M, Baize S, Padler-Karavani V, Geisbert TW, Diskin R.(2020). Rational design of universal immunotherapy for TfR1-tropic arenaviruses. Nat Commun. 11(1):67.

  19. Paul A, Bachar Abramovitch S, Padler-Karavani V. (2020). Specific Detection of Neu5Gc in Animal Tissues by Immunohistochemistry. Methods Mol Biol. 59-72.

  20. Le Berre L, Danger R, Mai HL, Amon R, Leviatan Ben-Arye S, Bruneau S, Senage T, Perreault H, Teraiya M, Nguyen TVH, Le Tourneau T, Yu H, Chen X, Galli C, Roussel JC, Manez R, Costa C, Brouard S, Galinanes M, Harris KM, Gitelman S, Cozzi E, Charreau B, Padler-Karavani V, Soulillou JP. (2019). Elicited and pre-existing anti-Neu5Gc antibodies differentially affect human endothelial cells transcriptome. Xenotransplantation. e12535

  21. Perota A, Lagutina I, Duchi R, Zanfrini E, Lazzari G, Judor JP, Conchon S, Bach JM, Bottio T, Gerosa G, Costa C, Galiñanes M, Roussel JC, Padler-Karavani V, Cozzi E, Soulillou JP, Galli C. (2019). Generation of cattle knockout for galactose-α1,3-galactose and N-glycolylneuraminic acid antigens. Xenotransplantation. e12524

  22. Leviatan Ben-Arye S, Schneider C, Yu H, Bashir S, Chen X, von Gunten S, Padler-Karavani V.(2019). Differential Recognition of Diet-Derived Neu5Gc-Neoantigens on Glycan Microarrays by Carbohydrate-Specific Pooled Human IgG and IgA Antibodies. Bioconjug Chem. 1565-1574.

  23. Ng PSK, Day CJ, Atack JM, Hartley-Tassell LE, Winter LE, Marshanski T, Padler-Karavani V, Varki A, Barenkamp SJ, Apicella MA, Jennings MP (2019). Nontypeable Haemophilus influenzae Has Evolved Preferential Use of N-Acetylneuraminic Acid as a Host Adaptation. MBio. 00422-19.

  24. Rousse J, Salama A, Leviatan Ben-Arye S, Hruba P, Slatinska J, Evanno G, Duvaux O, Blanchard D, Yu H, Chen X, Bach JM, Padler-Karavani V, Viklicky O, Soulillou JP. (2019). Quantitative and qualitative changes in anti-Neu5Gc antibody response following rabbit anti-thymocyte IgG induction in kidney allograft recipients. Eur J Clin Invest.2936-2947.

  25. Reuven EM, Leviatan Ben-Arye S, Yu H, Duchi R, Perota A, Conchon S, Bachar Abramovitch S, Soulillou JP, Galli C, Chen X, Padler-Karavani V. (2019). Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy. ACS Nano. 26;13(3):2936-2947.

  26. Bottigliengo D., Acar AS., Sciannameo V., Lorenzoni G., Bejko J., Bottio T., Cozzi E., Vadori M., Soulillou JP., Roussel JC., Torneau TL., Senage T., Mañez R., Costa C., Padler-Karavani V.,Scali S, Carrozzini M., Fiorello E., Fusca S., Gerosa G., Baldi I., Berchialla P., Gregori D. (2019). “Clinical Stability” and Propensity Score Matching in Cardiac Surgery: is the clinical evaluation of treatment efficacy algorithm dependent in small sample size settings? Epidemiology Biostatistics and Public Health. Volume 16, No.1

  27. Bashir S, Leviatan Ben Arye S, Reuven EM, Yu H, Costa C, Galiñanes M, Bottio T, Chen X, Padler-Karavani V. (2018). Presentation mode of glycans affect recognition of human serum anti-Neu5Gc IgG antibodies. Bioconjug Chem. 6;30(1):161-168

  28. Amon R, Grant OC, Leviatan Ben-Arye S, Makeneni S, Nivedha AK, Marshanski T, Norn C, Yu H, Glushka JN, Fleishman SJ, Chen X, Woods RJ, Padler-Karavani V. (2018). A combined computational-experimental approach to define the structural origin of antibody recognition of sialyl-Tn, a tumor-associated carbohydrate antigen. Sci Rep. 8(1):10786.

  29. Paul A, Padler-Karavani V. (2018). Evolution of sialic acids: Implications in xenotransplant biology. Xenotransplantation. 22:e12424.

  30. Samraj AN, Bertrand KA, Luben R, Khedri Z, Yu H, Nguyen D, Gregg CJ, Diaz SL, Sawyer S, Chen X, Eliassen H, Padler-Karavani V, Wu K, Khaw KT, Willett W, Varki A. (2018). Polyclonal human antibodies against glycans bearing red meat-derived non-human sialic acid N-glycolylneuraminic acid are stable, reproducible, complex and vary between individuals: Total antibody levels are associated with colorectal cancer risk. PLoS One. 13(6):e0197464.

  31. Shanthamurthy CD, Jain P, Yehuda S, Monteiro JT, Leviatan Ben-Arye S, Subramani B, Lepenies B, Padler-Karavani V, Kikkeri R. (2018). ABO Antigens Active Tri- and Disaccharides Microarray to Evaluate C-type Lectin Receptor Binding Preferences. Sci Rep. 8(1):6603.

  32. Lop L, Padler-Karavani V, Cozzi E. (2018). Xenotransplantation: The Way beyond and Ahead toward Clinical Application. J Immunol Res. 6191359.

  33. Gade M, Alex C, Leviatan Ben-Arye S, Monteiro JT, Yehuda S, Lepenies B, Padler-Karavani V, Kikkeri R. (2018). Microarray Analysis of Oligosaccharide-Mediated Multivalent Carbohydrate-Protein Interactions and Their Heterogeneity. Chembiochem 9,(11) 1170-1177.

  34. Mai HL, Treilhaud M, Ben-Arye SL, Yu H, Perreault H, Ang E, Trébern-Launay K, Laurent J, Malard-Castagnet S, Cesbron A, Nguyen TVH, Brouard S, Rostaing L, Houssel-Debry P, Legendre C, Girerd S, Kessler M, Morelon E, Sicard A, Garrigue V, Karam G, Chen X, Giral M, Padler-Karavani V, Soulillou JP. (2018). Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation. Transplant Direct. 4(4):e357.

  35. Amon R, Ben-Arye SL, Engler L, Yu H, Lim N, Berre LL, Harris KM, Ehlers MR, Gitelman SE, Chen X, Soulillou JP, Padler-Karavani V. (2017). Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy. Oncotarget. 8(68):112236-112244.

  36. Leviatan Ben-Arye S, Yu H, Chen X, Padler-Karavani V. (2017). Profiling Anti-Neu5Gc IgG in Human Sera with a Sialoglycan Microarray Assay. J Vis Exp. (125).

  37. Padler-Karavani V. (2016). Glycan Microarray Reveal the Sweet Side of Cancer Vaccines. Cell Chem Biol. 23(12):1446-1447.

  38. Yadav R, Leviatan Ben-Arye S, Subramani B, Padler-Karavani V, Kikkeri R. (2016). Screening of Neu5Acα(2-6)gal isomer preferences of siglecs with a sialic acid microarray. Org Biomol Chem.14(46):10812-10815.

  39. Reuven EM, Leviatan Ben-Arye S, Marshanski T, Breimer ME, Yu H, Fellah-Hebia I, Roussel JC, Costa C, Galiñanes M, Mañez R, Le Tourneau T, Soulillou JP, Cozzi E, Chen X, Padler-Karavani V. (2016). Characterization of immunogenic Neu5Gc in bioprosthetic heart valves. Xenotransplantation. (5):381-92. 

  40. Langereis MA, Bakkers MJ, Deng L, Padler-Karavani V, Vervoort SJ, Hulswit RJ, van Vliet AL, Gerwig GJ, de Poot SA, Boot W, van Ederen AM, Heesters BA, van der Loos CM, van Kuppeveld FJ, Yu H, Huizinga EG, Chen X, Varki A, Kamerling JP, de Groot RJ. (2015). Complexity and Diversity of the Mammalian Sialome Revealed by Nidovirus Virolectins. Cell Rep. 11(12):1966-78.

  41. Padler-Karavani V. (2014). Aiming at the sweet side of cancer: aberrant glycosylation as possible target for personalized-medicine. Cancer Lett. 352(1):102-12. 

  42. Amon R, Reuven EM, Leviatan Ben-Arye S, Padler-Karavani V. (2014). Glycans in immune recognition and response. Carbohydr Res. 389:115-22. 

  43. Padler-Karavani V#, Hurtado-Ziola N#, Chang YC, Sonnenburg JL, Ronaghy A, Yu H, Verhagen A, Nizet V, Chen X, Varki N, Varki A, Angata T. (2014). Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primates. FASEB J. 28(3):1280-93 (# equally contributed).

  44. UCSD blog: http://ucsdhealthsciences.tumblr.com/post/77737274933/the-red-queen-effect-writ-small-in-what-amounts. Featured on FASEB March 2014 issue; “Scientists Learn How Pathogens Hack Our Immune Systems To Go Undetected”: http://www.eurekalert.org/pub_releases/2014-02/foas-slh022714.php

  45. Scobie L#, Padler-Karavani V#, Le Bas-Bernardet S, Crossan C, Blaha J, Matouskova M, Hector RD, Cozzi E, Vanhove B, Charreau B, Blancho G, Bourdais L, Tallacchini M, Ribes JM, Yu H, Chen X, Kracikova J, Broz L, Hejnar J, Vesely P, Takeuchi Y, Varki A, Soulillou JP. (2013). Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenografts. J Immunol. 191(6):2907-15 (# equally contributed).

  46. Kikkeri R, Padler-Karavani V, Diaz S, Verhagen A, Yu H, Cao H, Langereis MA, De Groot RJ, Chen X, Varki A. (2013). Quantum dot nanometal surface energy transfer based biosensing of sialic acid compositions and linkages in biological samples. Anal Chem. 85(8):3864-70.

  47. Padler-Karavani V, Tremoulet AH, Yu H, Chen X, Burns JC, Varki A. (2013). A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease. PLoS One. 8(3):e58443.

  48. Wang X, Mitra N, Secundino I, Banda K, Cruz P, Padler-Karavani V, Verhagen A, Reid C, Lari M, Rizzi E, Balsamo C, Corti G, De Bellis G, Longo L; NISC Comparative Sequencing Program, Beggs W, Caramelli D, Tishkoff SA, Hayakawa T, Green ED, Mullikin JC, Nizet V, Bui J, Varki A. (2012). Specific inactivation of two immunomodulatory SIGLEC genes during human evolution. Proc Natl Acad Sci 109(25):9935-40. 

  49. UCSD News release: http://health.ucsd.edu/news/releases/Pages/2012-06-04-infectious-disease-shaped-human-origins.aspx

  50. Padler-Karavani V#, Song X#, Yu H, Hurtado-Ziola N, Huang S, Muthana S, Chokhawala HA, Cheng J, Verhagen A, Langereis MA, Kleene R, Schachner M, de Groot RJ, Lasanajak Y, Matsuda H, Schwab R, Chen X, Smith DF, Cummings RD, Varki A. (2012). Cross-comparison of protein recognition of sialic acid diversity on two novel sialoglycan microarrays. J Biol Chem. 287(27):22593-608 (# equally contributed).

  51. Lu Q#, Padler-Karavani V#, Yu H, Chen X, Wu S-L, Varki A and Hancock WS. (2012) LC-MS analysis of polyclonal human anti-Neu5Gc Xeno-autoantibodies IgG subclass and partial sequence using multi-step IVIG affinity purification and multi-enzymatic digestion. Anal Chem 84(6):2761-8 (# equally contributed).

  52. Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, Muthana S, Chokhawala HA, Cao H, Secrest P, Friedmann-Morvinski D, Singer O, Ghaderi D, Verma IM, Liu YT, Messer K, Chen X, Varki A, Schwab R. (2011) Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res. 71(9):3352-63.

  53. Padler-Karavani V, Varki A. (2011) Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk. Xenotransplantation. 18(1):1-5.

  54. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S and Varki A. (2010) Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotech. 28(8):863-7. 

  55. Taylor RE, Gregg CJ, Padler-Karavani V, Ghaderi D, Yu H, Huang S, Sorensen RU, Chen X, Inostroza J, Nizet V and Varki A. (2010) Novel mechanism for the generation of human xeno-auto-antibodies against the non-human sialic acid N-glycolylneuraminic acid. J Exp Med. 207(8): 1637-1646.

  56. Pham T, Gregg CJ, Karp F, Chow R, Padler-Karavani V, Cao H, Chen X, Witztum JL, Varki NM and Varki A. (2009) Evidence for a Novel Human-specific Xeno-Auto-Antibody Response Against Vascular Endothelium. Blood. 114(25): 5225-35.

  57. Hedlund M, Padler-Karavani V, Varki N, and Varki A. (2008) Evidence for a Human-Specific Mechanism for Diet and Antibody-Mediated Inflammation in Carcinoma Progression. Proc Natl Acad Sci U S A. 105(48): 18936-41.

  58. Padler-Karavani V, Yu H, Cao H, Chokhawala H, Karp F, Varki N, Chen X and Varki A. (2008) Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease. Glycobiology. 18(10): 818-30.

  59. Aviezer-Hagai K#, Padler-Karavani V#, Nelson N. (2003) Biochemical support for the V-ATPase rotary mechanism: antibody against HA-tagged Vma7p or Vma16p but not Vma10p inhibits activity. J Exp Biol. 206: 3227-37. (# equally contributed).

bottom of page